Zydus gets USFDA tentative nod for Empagliflozin Tablets Medical Dialogues Bureau11 April 2020 6:47 AM GMTAhmedabad: Zydus Cadila has received tentative approval from the USFDA to market Empagliflozin Tablets, in the strengths of 10 mg and 25 mg (US RLD: Ja...
Zydus gets USFDA nod for Lamotrigine Extended-Release Tablets for seizures Medical Dialogues Bureau3 April 2020 8:02 AM GMTAhmedabad: Zydus Cadila has received final approval from the USFDA to market Lamotrigine Extended-Release Tablets USP in the strengths of 25 mg, 50 mg,...
Zydus gets USFDA tentative nod for Carbidopa, Levodopa Extended-Release Capsules Medical Dialogues Bureau31 March 2020 8:00 AM GMTAhmedabad: Zydus Cadila has received tentative approval from the USFDA to market Carbidopa and Levodopa Extended-Release Capsules in the strengths of...
Cadila Healthcare BOD approves transfer of Animal Healthcare Business to Zydus Animal Health and Investments Limited Medical Dialogues Bureau15 March 2020 3:30 AM GMTNew Delhi: Cadila Healthcare Ltd. has recently announced that the Board of Directors at its meeting, has approved the transfer of Animal Healthcare Bus...
Zydus, XOMA enter into licensing agreement for IL-2-Based Immuno-Oncology Therapy Medical Dialogues Bureau11 March 2020 3:30 AM GMTAhmedabad, Emeryville: Zydus Cadila and XOMA Corporation have announced they have entered into a licensing agreement to advance an IL-2-based immuno-on...
Zydus gets DCGI nod for Phase I clinical trial of ZYBK2b to treat Rheumatoid Arthritis Medical Dialogues Bureau4 March 2020 5:04 AM GMTZYBK2 has been specifically designed to inhibit HLA-DRB1 Shared Epitope (SE) that determines the susceptibility of a person to develop rheumatoid...
Zydus Cadila gets USFDA nod for Fluocinonide cream to treat skin conditions Medical Dialogues Bureau12 Feb 2020 7:21 AM GMTFluocinonide cream USP, 0.1 per cent, approved by USFDA is indicated to treat a variety of skin conditions such as psoriasis, eczema, dermatitis,...
Zydus Cadila receives warning letter from USFDA for Moraiya-based formulation facility Medical Dialogues Bureau5 Nov 2019 7:27 AM GMTNew Delhi: Drug firm Zydus Cadila on Monday said it has received a warning letter from the US health regulator for its Moraiya-based formulation...
Cadila Healthcare largest API manufacturing site clears USFDA inspection Medical Dialogues Bureau12 Oct 2019 6:11 AM GMTThe US Food and Drug Administration (USFDA) inspected the company's active pharmaceutical ingredients (API) manufacturing facility at Dabhasa from Octo...
Zydus Cadila gets USFDA nod for Colesevelam Hydrochloride tablets for lowering cholesterol Medical Dialogues Bureau10 Oct 2019 6:04 AM GMTZydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Colesevelam Hydrochloride tablets, i...
CDSCO warns against Cancer Causing Impurities in anti-acidity drug Ranitidine, writes to state drug controllers Farhat Nasim25 Sep 2019 7:49 AM GMTNew Delhi: To ensure patient safety, the country's apex drug regulatory body, Central Drugs Standard Control Organisation (CDSCO) has ordered an...
Zydus Cadila wins DCGI nod for marketing rabies drug Twinrab Medical Dialogues Bureau3 Sep 2019 4:30 AM GMT'The novel biologic which will be marketed under the brand name, Twinrab, is indicated in combination with rabies vaccine for rabies post-exposure prop...
